Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2003

01-02-2003

A Comparison of Risk Perception and Psychological Morbidity in Women with Ductal Carcinoma in situ and Early Invasive Breast Cancer

Authors: Eileen Rakovitch, Edmee Franssen, John Kim, Ida Ackerman, Jean-Philippe Pignol, Lawrence Paszat, Kathleen I. Pritchard, Cindy Ho, Donald A. Redelmeier

Published in: Breast Cancer Research and Treatment | Issue 3/2003

Login to get access
Metadata
Title
A Comparison of Risk Perception and Psychological Morbidity in Women with Ductal Carcinoma in situ and Early Invasive Breast Cancer
Authors
Eileen Rakovitch
Edmee Franssen
John Kim
Ida Ackerman
Jean-Philippe Pignol
Lawrence Paszat
Kathleen I. Pritchard
Cindy Ho
Donald A. Redelmeier
Publication date
01-02-2003
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2003
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1021853302033

Other articles of this Issue 3/2003

Breast Cancer Research and Treatment 3/2003 Go to the issue

OriginalPaper

FosB is Highly Expressed in Normal Mammary Epithelia, but Down-Regulated in Poorly Differentiated Breast Carcinomas

Volume Contents

Subject Index, Volume 77

Authors Index

Author Index, Volume 77

Abstract List

The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months

OriginalPaper

Breast Cancer Risk and Methylenetetrahydrofolate Reductase Polymorphism

OriginalPaper

Cell Proliferation, Apoptosis, and Expression of Cyclin D1 and Cyclin E as Potential Biomarkers in Tamoxifen-Treated Mammary Tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits